Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Andrew Bottomley(Bradford Teaching Hospitals NHS Foundation Trust), Daniil Stroyakovskiy(Shikoku Cancer Center), Ragini R. Kudchadkar, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michele Maio(University of Siena), Michael P. Brown(South Australia Pathology), Jacob Schachter, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Catherine Barrow, Michal Kiciński(European Organisation for Research and Treatment of Cancer), Thierry Lesimple, Dirk Schadendorf(National Center for Tumor Diseases), Corneel Coens(European Organisation for Research and Treatment of Cancer), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Friedegund Meier(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Justyna Mierzynska(European Organisation for Research and Treatment of Cancer), Andrey Meshcheryakov(Russian Cancer Research Center NN Blokhin), Inge Marie Svane(Copenhagen University Hospital), Alexander M.M. Eggermont(University Medical Center Utrecht), Peter Hersey(The University of Sydney), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Shahneen Sandhu(The University of Melbourne), Pietro Quaglino(Department of Medical Sciences), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Paola Queirolo, Alfons J.M. van den Eertwegh(Amsterdam University Medical Centers), Stéphane Dalle(Hospices Civils de Lyon), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), James Larkin(Trinity College Dublin), Gerald P. Linette(University of Pennsylvania), Laurent Mortier, Susana Puig(Instituto de Salud Carlos III), Stefan Suciu(St James's University Hospital), Matteo S. Carlino(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Leonel F. Hernandez‐Aya(Washington University in St. Louis), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Anna Maria Di Giacomo(University of Siena), Xinni Song, Victoria Atkinson(Greenslopes Private Hospital), Rutger H.T. Koornstra(Radboud University Nijmegen), Adnan Khattak(Edith Cowan University), Mario Mandalà(University of Perugia)
Cited by 72
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k